SOLV Solventum Corp
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1964738 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.8%
TTM net income YoY-89.8%
TTM EPS YoY-89.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin54.8%
Operating margin5.6%
Net margin1.9%
FCF margin0.0%
EBITDA margin9.6%
Returns
ROE3.2%
ROA1.1%
ROIC (approx.)4.7%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets66.1%
Debt / equity1.05x
Current ratio1.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.99x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $8.32B | $8.25B |
| Gross profit | $4.45B | $4.59B |
| R&D expense | $739.00M | $775.00M |
| SG&A expense | $3.08B | $2.78B |
| Operating income | $2.18B | $1.04B |
| Pretax income | $1.71B | $605.00M |
| Income tax | $157.00M | $127.00M |
| Net income | $1.56B | $479.00M |
| EBITDA | $2.67B | $1.59B |
| EPS (basic) | 8.94 | 2.77 |
| EPS (diluted) | 8.88 | 2.76 |
| Weighted avg. shares (diluted) | 175.30M | 173.70M |
| Balance sheet | ||
| Cash & equivalents | $878.00M | $762.00M |
| Receivables | $1.03B | $1.04B |
| Inventory | $1.07B | $965.00M |
| Current assets | $3.86B | $3.25B |
| PP&E, net | $1.33B | $1.62B |
| Goodwill | $5.70B | $6.38B |
| Intangibles | $2.59B | $2.54B |
| Total assets | $14.29B | $14.46B |
| Current liabilities | $3.14B | $2.70B |
| Short-term debt | $0 | $200.00M |
| Long-term debt | $5.04B | $7.81B |
| Total debt | $5.04B | $8.01B |
| Total liabilities | $9.24B | $11.50B |
| Shareholders' equity | $5.05B | $2.96B |
| Net debt | $4.16B | $7.25B |
| Shares outstanding | 173.49M | 172.79M |
| Cash flow statement | ||
| Operating cash flow | $369.00M | $1.19B |
| Capital expenditure | $379.00M | $380.00M |
| Free cash flow | -$10.00M | $805.00M |
| Investing cash flow | $2.80B | -$380.00M |
| Financing cash flow | -$3.06B | -$240.00M |
| Depreciation & amortization | $489.00M | $555.00M |
| Stock-based compensation | $161.00M | $112.00M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.